^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

BCR-ABL1 F317V

i
Entrez ID:
Phase 1
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
07/27/2023
Initiation :
06/29/2015
Primary completion :
06/01/2025
Completion :
06/01/2025
ABL1 • BCR • PDGFRB • CRLF2 • JAK3 • CSF1R • TSLP
|
BCR-ABL1 E255K • BCR-ABL1 V299L • BCR-ABL1 F317L • ABL1 T315I • BCR-ABL1 L248V • BCR-ABL1 Q252H • BCR-ABL1 F317V • JAK3 mutation • ABL1 E255K • BCR-ABL1 F317C • BCR-ABL1 T315A • ABL1 F317L • BCR-ABL1 L248R
|
dasatinib • Jakafi (ruxolitinib) • dexamethasone